Please refer to Molecular Genetics - Austin Pathology for specific testing details and request form for ordering.
Haematolymphoid Disorders NGS Panel Gene List (73): ABL1, ASXL1, BAD, BAX, BCL2, BCL2L1, BCOR, BIRC3, BRAF, BTK, CALR, CARD11, CBL, CCND1, CD274, CD79B, CEBPA, CSF3R, CXCR4, DDX41, DNMT3A, EGR2, ETNK1, ETV6, EZH2, FBXW7, FLT3, FYN, GATA1, GATA2, ID3, IDH1, IDH2, IRF8, JAK2, KIT, KRAS, MAP2K1, MEN1, MPL, MYD88, NOTCH1, NOTCH2, NPM1, NRAS, PDCD1LG2, PHF6, PIM1, PLCG1, PLCG2, PPM1D, PTEN, PTPN11, RHOA, RUNX1, SETBP1, SF3B1, SH2B3, SMARCA2, SMARCA4, SRSF2, STAG2, STAT3, STAT5B, STAT6, TET2, TP53, U2AF1, UBA1, UBTF, WT1, XPO1, ZRSR2.
Myeloproliferative Neoplasm (MPN) NGS Panel Gene List (23): ASXL1, CALR, CBL, CSF3R, DNMT3A, ETNK1, EZH2, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NRAS, RUNX1, SETBP1, SF3B1, SRSF2, SH2B3, TET2, TP53, U2AF1
Haematolymphoid Disorders and Myeloproliferative Neoplasms (MPN) NGS Panel utilises massively parallel sequencing technology to assess genetic variants (also referred to as mutations) that are important in different haematolymphoid disorders. Genes assessed in these panels are currently known to have important diagnostic, prognostic and therapeutic implications.
Any specific FLT3 or NPM1 requests must add test code AFLTNP.
If NPM1 MRD (Minimal Residual Disease) is requested using ANPM1 test code, sample must be received within 48 hours of collection. For JAK2 exon 14 requests use test code AJAK2, unless JAK2 exon 12 stated then use test code AMYNGS. Note that some of these genes are also tested using the solid tumour NGS panel for colorectal cancer, lung cancer or melanoma. Please refer to relevant solid tumour NGS panels.
